Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) acquired by Federated Hermes Inc.

VaselineSeptember 16, 2024

0 4 minutes read

Federated Hermes Inc. increased its position in ADMA Biologics, Inc. (NASDAQ:ADMA – Free Report) by 15.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,969,811 shares of the biotechnology company’s stock after acquiring an additional 263,677 shares during the quarter. Federated Hermes Inc. owned 0.85% of ADMA Biologics worth $22,022,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mesirow Institutional Investment Management Inc. acquired a new stake in ADMA Biologics in the first quarter worth approximately $17,221,000. Castleark Management LLC acquired a new stake in ADMA Biologics in the first quarter valued at $5,400,000. Hillsdale Investment Management Inc. raised its holdings in ADMA Biologics by 41,893.3% in the first quarter. Hillsdale Investment Management Inc. now owns 629,900 shares of the biotechnology company’s stock worth $4,157,000 after purchasing an additional 628,400 shares during the last quarter. Russell Investments Group Ltd. boosted its position in ADMA Biologics by 90.7% in the first quarter. Russell Investments Group Ltd. now owns 1,169,207 shares of the biotechnology company’s stock valued at $7,717,000 after purchasing an additional 556,175 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its position in shares of ADMA Biologics by 152.2% in the first quarter. BNP Paribas Financial Markets now owns 732,920 shares of the biotechnology company’s stock worth $4,837,000 after acquiring an additional 442,315 shares in the last quarter. 75.68% of the shares are currently owned by institutional investors and hedge funds.

Changes in Analyst Ratings

A number of research analysts recently commented on the company. HC Wainwright boosted their target price on ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a report on Monday, August 12th. Cantor Fitzgerald boosted their price target on ADMA Biologics from $15.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Finally, Mizuho raised their target price on shares of ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, June 20th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. ADMA Biologics has a consensus rating of “Buy” and an average price target of $15.50, according to MarketBeat.

Want more great investment ideas?

Get the latest analysis on ADMA Biologics

Indoor activity

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the transaction, the director now owns 153,941 shares of the company’s stock, valued at $2,843,290.27. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible via this hyperlink. In other news, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the transaction, the director now owns 153,941 shares of the company’s stock, valued at $2,843,290.27. The sale was disclosed in a filing with the SEC, which is accessible via this hyperlink. Also, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the sale, the chief executive officer now directly owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. The disclosure for this sale can be found here. Over the last three months, insiders have sold 466,900 shares of company stock worth $8,224,121. Company insiders own 3.70% of the company’s shares.

ADMA Biologics Trading Up 2.5%

NASDAQ:ADMA opened at $18.09 on Monday. The company has a market cap of $4.22 billion, a PE ratio of -904.50 and a beta of 0.61. The company’s 50-day moving average is $15.07, and its two-hundred-day moving average is $10.52. The company has a quick ratio of 2.80, a current ratio of 6.87, and a debt-to-equity ratio of 0.74. ADMA Biologics, Inc. it has a 52-week low of $3.06 and a 52-week high of $19.34.

ADMA Biologics (NASDAQ:ADMA – Get Your Free Report ) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The firm had revenue of $107.20 million for the quarter, compared to analysts’ expectations of $86.44 million. During the same period last year, the company posted ($0.02) earnings per share. The company’s revenue for the quarter was up 78.4% year over year. On average, analysts predict that ADMA Biologics, Inc. it will post 0.49 EPS for the current year.

About ADMA Biologics

(Free report)

ADMA Biologics, Inc, a biopharmaceutical company, is engaged in the development, manufacture and commercialization of plasma-derived specialty biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The Company offers BIVIGAM, an intravenous immunoglobulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of IP; and Nabi-HB for the treatment of acute exposure to blood containing hepatitis B surface antigen and other listed hepatitis B exposures.